Bristol-Myers anticipates significant decline in US clopidogrel sales as patent lapses

17 May 2012

GenericsWeb, a patent analysis and search company, recently published an article based on its proprietary Pipeline Patent Intelligence that analyses opportunities in launching generic versions of French drug major Sanofi (Euronext: SAN) and US partner Bristol Myers Squibb’s (NYSE: BMY) blockbuster platelet aggregation inhibitor clopidogrel (brand names Plavix and Iscover).

US sales of Plavix - which lost patent protection in the USA yesterday (May 17) - increased by 8% in 2011, generating $6.62 billion of the $7.09 billion gained globally; resulting in a global sale increase of 6%. Sales in non-US markets declined 9%. Bristol-Myers has said it no longer plans to actively promote Plavix.

The article by GenericsWeb highlights the following observations in relation to generic clopidogrel:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK